Key Highlights
- ARK Invest purchased 83,764 shares of CoreWeave valued at approximately $6.9M, targeting the Nvidia-backed AI cloud infrastructure provider
- ARK established its inaugural direct stake in OpenAI, purchasing nearly 349,000 shares distributed among three separate funds
- ARK expanded positions in Kodiak AI, Oklo nuclear energy, DoorDash, plus genomics companies Arcturus and GeneDx
- ARK divested 745K shares of Strata Critical Medical while reducing exposure to Teradyne, Pinterest, and Veracyte
- ARKK has declined approximately 12% year to date, experiencing $1.2 billion in net outflows during the past 12 months
Cathie Wood’s ARK Invest executed a strategic expansion into artificial intelligence, genomics, and clean energy sectors last week, deploying millions in fresh allocations while paring back multiple existing positions.
The most substantial acquisition involved CoreWeave, an Nvidia-backed cloud infrastructure provider specializing in GPU-powered data centers designed for AI computational demands. ARK accumulated 83,764 shares over three consecutive trading sessions — March 30, 31, and April 1 — representing an investment of approximately $6.9 million calculated at the $82 closing price.
CoreWeave, Inc. Class A Common Stock, CRWV
CoreWeave serves prominent clients including Google and Microsoft. The company disclosed fourth-quarter revenue reaching $1.57 billion in February, representing 110% year-over-year growth. First-quarter projections ranging from $1.9 to $2 billion fell short of the $2.29 billion analyst consensus.
Bank of America elevated CoreWeave to a buy rating in March, establishing a $100 price objective. Analysts highlighted the company’s positioning within what they characterize as a $79 billion AI infrastructure marketplace.
ARK simultaneously established its inaugural direct investment in OpenAI, the organization responsible for ChatGPT. Three ARK funds — ARKF, ARKK, and ARKW — collectively acquired 348,995 shares or units via a Series C allocation. ARK characterized this transaction as its first direct cap table participation in OpenAI.
Expansion into Autonomous Transportation and Nuclear Power
ARK’s ARKQ fund acquired 230,000 shares of Kodiak AI, an organization specializing in autonomous trucking solutions and AI-driven logistics. ARK simultaneously purchased approximately 56,000 shares of Oklo, a nuclear energy enterprise developing advanced fission technology.
DoorDash represented another strategic addition, with ARK increasing its consumer platform allocation through the food delivery operator.
Within genomics, ARK’s ARKG fund secured more than 16,000 shares of Arcturus Therapeutics, which specializes in RNA therapeutic development. ARK additionally acquired 39,000 shares of GeneDx, a genetic testing and precision medicine provider, distributed between ARKG and ARKK.
Portfolio Reductions: Strata, Teradyne, and Pinterest Exits
Regarding divestments, ARK’s most significant exit by volume involved Strata Critical Medical. ARK disposed of 745,000 shares representing approximately $3 million in value.
ARK simultaneously decreased its allocation in Veracyte, a diagnostics provider, and reduced holdings in semiconductor testing company Teradyne. Pinterest, Discovery, and Japanese internet platform LY Corp faced similar reductions.
Wood has articulated publicly her expectation for a “great acceleration” in worldwide economic growth propelled by AI. She indicated AI training expenses are declining 75% annually while inference costs are dropping between 85% to 98% per year.
ARKK has fallen roughly 12% year to date, contrasted with a 3.8% decline in the S&P 500. The fund has recorded $1.2 billion in net outflows throughout the past 12 months.
CoreWeave concluded trading at $82.24 on April 2 and has gained 15% year to date.
